Kenneth Dickstein

Q: What Schools Are Affiliated With Kenneth Dickstein

Kenneth Dickstein is affiliated with the following schools: University of Bergen, Medical University of South Carolina, University of Stavanger, University of Groningen, Duke University

Kenneth Dickstein's AcademicInfluence.com Rankings

Kenneth Dickstein

Medical

#1770

World Rank

#2144

Historical Rank

Cardiology

#142

World Rank

#145

Historical Rank

medical Degrees

Kenneth Dickstein

Philosophy

#5315

World Rank

#8077

Historical Rank

Logic

#2617

World Rank

#3632

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Kenneth Dickstein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kenneth Dickstein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012]. (2012) (7792)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012) (7528)
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) (1999) (4830)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2010) (4824)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. (2020) (3083)
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). (2007) (3077)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC (2006) (2631)
How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. (2007) (2589)
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006) (2558)
Universal definition of myocardial infarction. (2015) (2234)
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II (2000) (1955)
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. (2004) (1917)
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). (2006) (1767)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. (2015) (1755)
Ferric carboxymaltose in patients with heart failure and iron deficiency. (2009) (1586)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial (2008) (1488)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006) (1406)
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. (2005) (1207)
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. (2006) (1170)
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial (2002) (1159)
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invit (2007) (911)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text (2006) (778)
Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. (1996) (754)
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE (2012) (740)
[Guidelines on the management of stable angina pectoris: executive summary]. (2006) (705)
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. (2005) (647)
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation (2011) (612)
Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine (2010) (596)
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity (2005) (544)
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial (2009) (525)
Effect of nesiritide in patients with acute decompensated heart failure. (2011) (516)
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology (2009) (484)
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. (2013) (438)
Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. (1994) (417)
[ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. (2006) (412)
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors (2020) (379)
[ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. (2006) (378)
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology (2007) (374)
Self‐care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology (2011) (356)
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. (2012) (335)
Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine (2015) (323)
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. (2012) (322)
Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure (1993) (298)
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study (2017) (288)
Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. (1995) (286)
Adherence of heart failure patients to exercise: barriers and possible solutions (2012) (283)
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. (2008) (268)
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. (2006) (264)
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. (2009) (256)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (2017) (248)
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidel (2006) (244)
Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure (2010) (239)
The European cardiac resynchronization therapy survey. (2009) (237)
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. (2009) (219)
Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388–2442 and Eur J Heart Fail 2008;10:933–989] (2009) (208)
Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. (1995) (207)
[Guidelines for cardiac pacing and cardiac resynchronization therapy]. (2008) (199)
Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012’[Eur Heart J 2012;33:1787–1847, doi:10.1093/eurheartj/ehs104 (2013) (199)
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. (2004) (195)
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. (2016) (192)
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document (2013) (183)
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. (2016) (182)
Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. (2009) (177)
Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure (2017) (175)
Rapid implementation of therapeutic hypothermia in comatose out‐of‐hospital cardiac arrest survivors (2006) (172)
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. (2018) (167)
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). (2009) (161)
Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure: A Comparative Analysis on Clinical and Prognostic Insights (2009) (159)
Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II (2008) (158)
Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. (2007) (158)
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT‐CHF (2016) (157)
Left bundle branch block as a risk factor for progression to heart failure (2007) (156)
C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. (2009) (147)
Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. (2015) (144)
Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. (1999) (143)
Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward (2010) (141)
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study (2012) (141)
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. (2009) (140)
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial (2013) (138)
Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study (2011) (136)
Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008 (2009) (133)
The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study (2019) (128)
2010 Focused Update of ESC Guidelines on device therapy in heart failure (2010) (128)
The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. (2015) (124)
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. (2008) (123)
Effect of aerobic exercise training on plasma levels of tumor necrosis factor alpha in patients with heart failure. (2001) (121)
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. (2019) (121)
Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study (2019) (115)
Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia (2009) (114)
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience (2005) (114)
A comparison of methodologies in detection of the anaerobic threshold. (1990) (110)
Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. (2002) (108)
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. (2018) (105)
The European CRT Survey: 1 year (9–15 months) follow‐up results (2012) (105)
Effects of losartan and captopril on mortality and morbidity after acute myocardial infarction: The OPTIMAAL randomized trial. (2002) (104)
Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study (2011) (103)
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia (2006) (103)
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. (2015) (100)
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study (2010) (98)
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. (2005) (95)
The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades (2011) (95)
Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. (2017) (94)
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. (1999) (94)
Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. (2009) (91)
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. (2007) (91)
CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? (2018) (90)
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes (2017) (89)
Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial (2017) (84)
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. (2005) (83)
Assessing the effect of exercise training in men with heart failure; comparison of maximal, submaximal and endurance exercise protocols. (2001) (82)
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text (2007) (82)
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. (2004) (82)
Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. (1995) (81)
Waist‐to‐hip ratio and mortality in heart failure (2018) (79)
Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction (2011) (78)
The Brugada syndrome : diagnostic criteria and cellular mechanisms (2001) (78)
Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines. (2018) (77)
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF (2017) (77)
Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High‐Risk Myocardial Infarction Database Initiative (2015) (76)
Soluble CD40 ligand in acute and chronic heart failure. (2005) (76)
Increased interleukin‐1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention (2012) (72)
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care (2020) (72)
The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. (2010) (70)
Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. (2006) (70)
New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. (2014) (68)
The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. (2015) (68)
Telerehabilitation in heart failure patients: The evidence and the pitfalls. (2016) (68)
Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus (2017) (67)
Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. (2003) (67)
Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. (2020) (67)
Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. (2014) (66)
Effect of exercise training in patients with heart failure: a pilot study on autonomic balance assessed by heart rate variability (2004) (65)
Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF (2018) (65)
Corrigendum to: ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012’ [Eur J Heart Fail 2012;14: 803–869] (2013) (63)
Clinical pharmacokinetics in heart failure. An updated review. (1988) (63)
Clinical Pharmacokinetics in Heart Failure (1988) (63)
Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. (2019) (62)
The prognostic importance of body mass index after complicated myocardial infarction. (2005) (61)
Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. (1993) (61)
Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction. (2007) (60)
Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF (2018) (58)
Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: the rationale, design and methodology of the HF‐Wii study; a multicentre randomized controlled trial (2015) (58)
The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE (2020) (58)
Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use (2019) (56)
Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction (2012) (55)
Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure (2019) (54)
Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. (1994) (54)
Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. (2015) (53)
Natriuretic peptides in detection of heart failure (1998) (51)
Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. (2005) (50)
Sildenafil in Heart Failure (SilHF). An investigator‐initiated multinational randomized controlled clinical trial: rationale and design (2013) (49)
Overview of emerging pharmacologic agents for acute heart failure syndromes (2008) (49)
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. (2018) (49)
Effectiveness of the European Society of Cardiology/Heart Failure Association website ‘heartfailurematters.org’ and an e‐health adjusted care pathway in patients with stable heart failure: results of the ‘e‐Vita HF’ randomized controlled trial (2018) (49)
The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. (2000) (49)
Inpatients are sicker than outpatients; finally it's evidence-based. (2010) (48)
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy (2017) (48)
Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. (2016) (48)
Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. (1993) (48)
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry (2015) (47)
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation (2017) (47)
Cardiac troponins I and T in patients with suspected acute coronary syndrome: a comparative study in a routine setting. (1998) (47)
[Calcium channel blockers in heart failure]. (1997) (47)
Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction (2018) (46)
Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. (1996) (45)
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. (2013) (45)
Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. (2007) (45)
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. (2001) (44)
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction (2021) (44)
Meta‐analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy (2013) (43)
Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives (2016) (42)
Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality: Findings From ASCEND-HF (2014) (42)
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). (2005) (42)
The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. (2011) (41)
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment (2019) (41)
Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. (2020) (41)
Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery disease. (2006) (41)
The problems of sleep and rest in the intensive care unit. (1971) (41)
The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. (1987) (41)
Validation of a computerized technique for detection of the gas exchange anaerobic threshold in cardiac disease. (1990) (40)
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. (2018) (39)
Acute and Chronic Heart Failure 2008 (2012) (39)
A randomised trial of a pre‐synaptic stimulator of DA2‐dopaminergic and α2‐adrenergic receptors on morbidity and mortality in patients with heart failure (2008) (38)
Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. (2001) (38)
Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial (2015) (38)
Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure: Results From the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) (2014) (38)
Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. (2013) (37)
Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative (2017) (37)
Guidelines for the diagnosis and treatment of Chronic Heart Failure : full (2005) (36)
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas (2018) (36)
Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction. (2006) (36)
Sex-based short- and long-term survival in patients following complicated myocardial infarction. (2006) (36)
The chemokine network in relation to infarct size and left ventricular remodeling following acute myocardial infarction. (2009) (36)
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. (2017) (36)
The data monitoring experience in the MOXCON trial. (2004) (36)
Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology (2019) (35)
Novel endotypes in heart failure: effects on guideline-directed medical therapy (2018) (35)
Rationale for and design of the TRUE‐AHF trial: the effects of ularitide on the short‐term clinical course and long‐term mortality of patients with acute heart failure (2017) (35)
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT‐CHF study (2018) (35)
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. (2004) (35)
Highly increased Troponin I levels following high-intensity endurance cycling may detect subclinical coronary artery disease in presumably healthy leisure sport cyclists: The North Sea Race Endurance Exercise Study (NEEDED) 2013 (2017) (35)
Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. (2020) (35)
Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: relation to indices of cardiac and renal function. (1995) (34)
Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. (1997) (34)
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II (2018) (32)
The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure (2012) (32)
Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting death in patients following acute myocardial infarction. (2007) (32)
Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction. (2009) (32)
Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. (1997) (31)
How do heart failure patients die (2002) (31)
The high-risk myocardial infarction database initiative. (2012) (31)
Successful treatment of heart failure with devices requires collaboration (2008) (30)
The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure. (2000) (30)
Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial (2020) (30)
Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial (2016) (30)
The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. (2011) (30)
Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure (2009) (30)
Association of beta‐blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched‐cohort analysis from the High‐Risk Myocardial Infarction Database Initiative (2017) (29)
The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure (2019) (28)
Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial (2012) (27)
The relationship between markers of extracellular cardiac matrix turnover: infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. (2014) (27)
Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. (1986) (27)
Diagnosis and assessment of the heart failure patient: the cornerstone of effective management (2005) (27)
Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies. (2019) (27)
Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From the Acute Study Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) (2013) (26)
Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. (2005) (26)
A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High‐Risk MI Database (2017) (26)
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). (2016) (25)
Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. (1998) (25)
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. (2018) (25)
Proteomic diversity of high‐density lipoprotein explains its association with clinical outcome in patients with heart failure (2018) (25)
A double-blind multiple crossover trial evaluating a transdermal nitroglycerin system vs placebo. (1985) (25)
What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative (2016) (25)
ELITE II and Val-HeFT are different trials: together what do they tell us? (2001) (24)
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets (2019) (24)
ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation (2013) (24)
Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction (2016) (24)
Reproducibility of cardiopulmonary exercise testing in men following myocardial infarction. (1988) (23)
A Comparison of Hypotensive Responses After Oral and Intravenous Administration of Enalapril and Lisinopril in Chronic Heart Failure (1987) (23)
Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. (2013) (23)
Hemodynamic, Hormonal, and Pharmacokinetic Aspects of Treatment with Lisinopril in Congestive Heart Failure (1987) (22)
Effect of simvastatin in preventing progression of carotid artery stenosis. (2001) (22)
Cardiac markers in the early hours of acute myocardial infarction: clinical performance of creatine kinase, creatine kinase MB isoenzyme (activity and mass concentration), creatine kinase MM and MB subform ratios, myoglobin and cardiac troponin T. (1996) (22)
Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388–2442 and Eur J Heart Fail 2008;10:933–989] (2008) (22)
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients (2014) (21)
Tumour biomarkers: association with heart failure outcomes (2020) (21)
European cardiac resynchronization therapy survey II: rationale and design. (2015) (21)
Clinical correlates and outcome associated with changes in 6‐minute walking distance in patients with heart failure: findings from the BIOSTAT‐CHF study (2019) (21)
Pharmacology and Clinical Use of the New ACE‐Inhibitor Moexipril (1995) (21)
The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction (2014) (21)
Guía de práctica clínica sobre el tratamiento de las valvulopatías = [Guide of clinical practice on the treatment of the valvulopatías] (2007) (21)
‘heartfailurematters.org’, an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions (2017) (20)
Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and ASIAN‐HF registries (2020) (20)
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure (2020) (20)
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction (2019) (20)
Effectiveness of an interactive platform, and the ESC/HFA heartfailurematters.org website in patients with heart failure: design of the multicentre randomized e‐Vita heart failure trial (2015) (20)
Effect of Gender on Outcomes After Cardiac Resynchronization Therapy in Patients With a Narrow QRS Complex: A Subgroup Analysis of the EchoCRT Trial (2016) (20)
Cardiac tamponade in systemic lupus erythematosus. (1988) (20)
Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction. (1991) (20)
Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. (2018) (20)
The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure (2006) (20)
The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. (1989) (20)
Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non‐sudden cardiac death in myocardial infarction survivors with heart failure (2019) (19)
Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. (2004) (19)
Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction (2021) (19)
Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial (2018) (19)
Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative (2019) (19)
Design of the Heart failure Endpoint evaluation of AII‐Antagonist Losartan (HEAAL) study in patients intolerant to ACE‐inhibitor (2008) (19)
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF (2021) (19)
Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. (2019) (18)
Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. (2020) (18)
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction (2020) (18)
Remote monitoring of cardiac implanted electronic devices: legal requirements and ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force report. (2020) (18)
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics (2015) (17)
Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. (1999) (17)
Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial (2018) (17)
Association between mean systolic and diastolic blood pressure throughout the follow‐up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High‐Risk Myocardial Infarction Database Initiative (2018) (17)
Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study (2019) (16)
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire (2021) (16)
Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. (2009) (16)
The role of objective health indicators and neuroticism in perceived health and psychological well-being among patients with chronic heart failure (1997) (16)
Coronary angiography in worsening heart failure: determinants, findings and prognostic implications (2017) (16)
A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure (2020) (15)
Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease (2002) (15)
Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction (2020) (15)
Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. (2016) (15)
Fatal intrathoracic haemorrhage after cardiopulmonary resuscitation and treatment with streptokinase and heparin. (1989) (14)
Acute and chronic hemodynamic effects of enalapril (MK-421) in congestive heart failure. (1984) (14)
Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. (2018) (14)
Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes. (1987) (14)
Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction (2020) (14)
Plasma atrial natriuretic factor concentration during maximal cardiopulmonary exercise in men with mild heart failure. (1990) (13)
Effects of Long‐term Enalapril Therapy on Cardiopulmonary Exercise Performance After Myocardial Infarction (1991) (13)
Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF (2020) (13)
Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. (2008) (13)
Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. (1994) (13)
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF (2020) (13)
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome (2020) (13)
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. (2017) (12)
Prevalence and incidence of intra‐ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE (2020) (12)
Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. (1994) (12)
Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction (2018) (12)
Prognostic usefulness of an increase of N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. (2003) (12)
Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. (2019) (12)
Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study (2020) (12)
Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. (2019) (12)
What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? (2003) (11)
BNP in acute coronary syndromes: the heart expresses its suffering. (2004) (11)
[Are emergency admissions to medical departments dependent on weather?]. (2000) (11)
Non‐adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography‐tandem mass spectrometry (results of a prospective multicentre study) (2021) (11)
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation (2019) (11)
Comparison of topical timolol vs betaxolol on cardiopulmonary exercise performance in healthy volunteers (1988) (11)
Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment (2005) (11)
The impact of morbid events on survival following hospitalization for complicated myocardial infarction (2006) (10)
Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. (1997) (10)
Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (2011) (10)
B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. (2009) (10)
Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure. (2018) (10)
Acute and long-term response to enalapril in congestive failure. (1984) (10)
Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). (2018) (10)
Practical guidelines for the use of converting enzyme inhibitors in congestive heart failure. (1987) (10)
Eff ects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure ( HEAAL study ) : a randomised , double-blind trial (2009) (9)
Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry (2022) (9)
A respiratory exchange ratio equal to 1 provides a reproducible index of submaximal cardiopulmonary exercise performance. (1993) (9)
Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. (1992) (9)
Rate Responsive Cardiac Pacing Using a Minute Ventilation Sensor (1993) (9)
Cardiac resynchronization therapy improves minute ventilation/carbon dioxide production slope and skeletal muscle capillary density without reversal of skeletal muscle pathology or inflammation. (2013) (9)
Can sedentary patients with heart failure achieve the beneficial effect of exercise training without moving? (2004) (9)
Developed in Collaboration With the European Heart Rhythm Association and the Sudden Cardiac Death) Management of Patients With Ventricular Arrhythmias and the Prevention of Practice Guidelines (Writing Committee to Develop Guidelines for (2007) (9)
Sex-Related Procedural Aspects and Complications in CRT Survey II: A Multicenter European Experience in 11,088 Patients. (2019) (9)
Drug Selection for Optimal Treatment of Hypertension in the Elderly (1997) (9)
Management of patients with heart failure: are internists as good as cardiologists? (2001) (9)
Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey (2017) (8)
The role of losartan in the management of patients with heart failure. (2001) (8)
Exercise training in congestive heart failure. A review of the current status. (2005) (8)
Genetic risk and atrial fibrillation in patients with heart failure (2020) (8)
The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure (2021) (8)
Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHESUS and OPTIMAAL trials (2018) (8)
Heart failure management programmes: Delivering the message (2005) (8)
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial (2022) (8)
Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization (2016) (7)
Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. (2022) (7)
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure (2021) (7)
What is New and of Special Interest to Nurses in the 2008 ESC Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure? (2008) (7)
Differences in biomarkers and molecular pathways according to age for patients with HFrEF. (2020) (7)
Linee guida ESC per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico 2008 = Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 (2009) (7)
Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF. (2021) (7)
Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative (2017) (7)
The effect of early converting enzyme inhibition on neurohumoral activation in acute myocardial infarction. (1993) (7)
N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. (2003) (7)
Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension. (1996) (6)
Pharmacotherapy following myocardial infarction - a review of current treatment practices (2000) (6)
Cardiac troponin T by Elecsys system and a rapid ELISA: analytical sensitivity in relation to the TropT (CardiacT) "bedside" test. (1998) (6)
Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF (2020) (6)
Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT‐HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) (2022) (6)
Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. (2020) (6)
The relationship between early plasma atrial natriuretic factor levels and exercise performance after myocardial infarction. (1993) (6)
The Added Value of Spiral Computed Tomographic Angiography After Lung Scintigraphy for the Diagnosis of Pulmonary Embolism (2004) (6)
Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE (2013) (6)
Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction (2018) (6)
Effect on exercise performance of enalapril therapy initiated early after myocardial infarction. Nordic Enalapril exercise Trial. (1993) (5)
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure (2018) (5)
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure (2022) (5)
Chronic right ventricular pacing, adverse remodelling, and CRT: an ounce of prevention? (2011) (5)
Sustained haemodynamic effects of enalapril in left ventricular failure. (1983) (5)
Impaired High‐Density Lipoprotein Function in Patients With Heart Failure (2020) (5)
Plasma N-terminal atrial natriuretic peptide predicts hospitalization in patients with heart failure. (1998) (5)
[Guidelines in cardiac pacing and resynchronization therapy]. (2007) (5)
Effect of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized clinical trial☆ (2003) (5)
Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT (2017) (5)
Diagnosing acute heart failure: the mathematician and the clinician. (2009) (5)
How should we analyse hospitalizations in clinical trials? (2003) (5)
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study (2021) (4)
[Practice guidelines 2007 for the treatment of arterial hypertension]. (2007) (4)
Successful management of severe congestive cardiac failure with enalapril. (1983) (4)
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. (2021) (4)
Clinical implications of low estimated protein intake in patients with heart failure (2022) (4)
OPTIMAAL investigators. (A. Coats Steering Committee and National Co-ordinator) Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventrivular dysfunction: the OPTIMAAL experience. (2005) (4)
Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence (2022) (4)
Cardiac myosin activation: will theory and practice coincide? (2011) (4)
Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. (2017) (4)
Albuminuria as a marker of systemic congestion in patients with heart failure (2022) (4)
Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues. (2015) (4)
Neurohormonal inhibition in heart failure, is there no limit? (2003) (4)
Distinct pathophysiological pathways in women and men with heart failure (2022) (4)
ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation (2012) (4)
Prediction of morbidity and mortality following myocardial infarction (2002) (4)
Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure (2020) (4)
Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure. (2022) (3)
Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials. (2021) (3)
[Cardiopulmonary exercise testing]. (1987) (3)
Pathophysiological pathways in patients with heart failure and atrial fibrillation (2021) (3)
Correction to: Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. (2020) (3)
399 A double blind randomised trial of CHF1035, a prejunctional stimulator of D A2‐dopaminergic and alpha2‐adrenergic receptors, in patients with congestive heart failure (2005) (3)
Clinical trials update from the European Society of Cardiology Meeting 2005: CIBIS‐III. Response to correspondence from R. Willenheimer et al. (2006) (3)
Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. (2019) (3)
Comparison of the effect of timolol versus betaxolol ophthalmic on cardiopulmonary exercise performance in healthy volunteers. (1989) (3)
What constitutes optimal neurohumoral antagonism in chronic heart failure? (2016) (3)
Predicting outcomes following CRT: the quest continues (2015) (3)
Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF (2021) (3)
The plight of the peer reviewer. (2002) (3)
Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II Registry. (2018) (3)
ACE inhibitor use in heart failure: would that it were so. (1999) (3)
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation (2022) (3)
Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez‐Selles (2007) (3)
Current Therapy of Congestive Heart Failure (1989) (3)
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure (2022) (3)
C-reactive protein in ischaemic cardiomyopathy: assessing vascular risk in heart failure. (2005) (3)
Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II (2019) (3)
Optimized Implementation of cardiac resynchronization therapy – a call for action for referral and optimization of care (2021) (3)
[Angiotensin-converting enzyme inhibitor in heart failure]. (1987) (2)
Which Patients with Heart Failure are Likely to Benefit from Participation in an Exercise Training Program? (1999) (2)
Increased pulmonary vascular resistance, right ventricular dysfunction, and reversible pulmonary vasoconstriction in type 2 pulmonary hypertension: who has it and are we missing a potential therapeutic target in patients with heart failure? (2015) (2)
Angiotensin II antagonists are superior to ACE inhibitors; David vs. Goliath (2000) (2)
A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. (2012) (2)
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE (2021) (2)
Appearances can deceive: even brave hearts can fail. (2004) (2)
Association of time‐to‐intravenous furosemide with mortality in acute heart failure: data from REPORT‐HF (2022) (2)
Negative exercise trials in heart failure: result or design? (1998) (2)
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. (2022) (2)
[Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity--secondary publication]. (2006) (2)
Exercise training in heart failure: time to go beyond surrogate endpoints (2000) (2)
Spanish results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). (2019) (2)
ACE inhibitors in heart failure: are they irreplaceable? (2001) (2)
Aliskiren, Enalapril, or Both in Heart Failure. (2016) (2)
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure (2022) (2)
Pharmacokinetics of Enalapril in Congestive Heart Failure (2012) (2)
Current clinical practice of cardiac resynchronization therapy in Turkey: Reflections from Cardiac Resynchronization Therapy Survey-II (2020) (2)
Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure. (1984) (2)
[Use of angiotensin II receptor blockaders in heart failure]. (2000) (2)
Inhibition of both neutral endopeptidase and endothelin converting enzyme lowers pulmonary pressures in congestive heart failure (2003) (2)
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes (2022) (2)
Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study (2010) (1)
Cardiac resynchronization in Poland – comparable procedural routines? Insights from CRT Survey II (2019) (1)
Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. (2022) (1)
Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. (2020) (1)
[Pro-atrial natriuretic factor is predictive for the clinical status of patients with heart failure]. (1996) (1)
Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. (2020) (1)
Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. (2020) (1)
Fibrillation : ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial (2012) (1)
A Global Perspective of Racial Differences and Outcomes in Patients Presenting with Acute Heart Failure. (2021) (1)
Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry (2018) (1)
Coronary heart disease C-reactive protein , infarct size , microvascular obstruction , and left-ventricular remodelling following acute myocardial infarction (2009) (1)
In the treatment of heart failure, faster may not always be better. (2002) (1)
Heart failure in the Middle East An Emerging Challenge in a Diverse Environment. (2015) (1)
Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma?: reply (2009) (1)
Methods Employed to Assess Left Ventricular Ejection Fraction in Patients Referred for Cardiac Resynchronization Therapy in Poland as Compared to other European Countries. Results from the European Cardiac Resynchronization Therapy Survey II. (2019) (1)
Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome (2023) (1)
EUROPEAN CARDIAC RESYNCHRONIZATION THERAPY SURVEY II: COMPARISON OF RESULTS IN GEORGIA WITH OTHER COUNTRIES. (2019) (1)
Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease (2023) (1)
Moexpril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension (1995) (1)
[Chronic heart failure--suggestion to a management program]. (1999) (1)
Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. (2018) (1)
Cardiac resynchronization therapy in seniors: when are we too old to deserve a device that makes us feel better and improves clinical outcomes? (2013) (1)
Contemporary practice of CRT implantation in scandinavia compared to Europe (2019) (1)
Effectiveness of an interactive platform , and the ESC / HFA website in patients with heart failure : design of the multicentre randomized eVita heart failure trial (2016) (1)
[Prioritization of hospital autopsies]. (2002) (1)
The Challenge of Implementing Heart Failure Management Programmes Throughout Europe (2006) (1)
Early clinical benefit after cardiac resynchronization therapy: fortunately, QRS width and ejection fraction are still the best predictors (2017) (1)
Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population (2022) (1)
Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the High-Risk-Myocardial-Infarction database (2020) (1)
Do real world data support and extend our ability to predict reverse remodelling following cardiac resynchronization therapy based on QRS morphology and width? (2017) (1)
The OPTIMAAL trial: losartan or captopril after acute myocardial infarction (2002) (1)
Time course of morbidity and mortality after a myocardial infarction complicated by left ventricular systolic dysfunction or heart failure (2003) (1)
Remote monitoring of patients with cardiac failure (2009) (1)
Plasma fibroblast growth factor 23 is associated with poor outcome and unsuccessful uptitration of guideline-recommended pharmacotherapy in patients with worsening heart failure (2016) (1)
The association of smoking to cardiovascular death differs according to age and sex following myocardial infarction complicated by heart failure or left ventricular dysfunction (2020) (1)
Early discharge (<3 days) following primary PCI is safe in low risk patients (2013) (1)
Novel Drugs and Current Therapeutic Approaches in the Treatment of Heart Failure (1996) (1)
Cardiac resynchronization therapy in Romania – results from the European Society of Cardiology CRT Survey II (2020) (1)
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT (2016) (0)
DYSGLYCEMIA, EJECTION FRACTION, AND THE RISK OF HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME (2019) (0)
745 Temporal changes between infarct size and ejection fraction following primary PCI assessed by cardiac magnetic resonance (2007) (0)
[Cardiac resynchronization therapy in heart failure--Norwegian guidelines]. (2014) (0)
Case 19: Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial (2006) (0)
[Is it dangerous to be admitted during weekends?]. (2001) (0)
826-3 Early elevation of C-terminal telopeptide of type I collagen is highly correlated with 30-day mortality in patients with myocardial infarction regardless of infarct localization (2004) (0)
A U-SHAPED RELATIONSHIP BETWEEN TOTAL CHOLESTEROL AND 90-DAY MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION IN PATIENTS NOT ON STATINS: RESULTS FROM THE OPTIMAAL RANDOMIZED TRIAL (2011) (0)
National healthcare expenditure influences CRT implantations- results from CRT Survey II with 11088 patients (2020) (0)
Anaerobic Threshold (2005) (0)
rognostic Value of Osteoprotegerin in eart Failure After Acute Myocardial Infarction (2016) (0)
European CRT Survey II – Bulgarian data (2018) (0)
CRT Devices in Heart Failure: Does the Patient Need a Pacemaker or Defibrillator? (2019) (0)
University of Dundee Using matrix assisted laser desorption ionisation mass spectrometry ( MALDI-MS ) profiling in order to predict clinical outcomes of patients with heart failure (2018) (0)
Does the presence of mitral regurgitation strengthen or weaken the indication for cardiac resynchronization therapy? (2016) (0)
Thepharmacokinetics ofenalapril inhospitalized patients with congestive heart failure (1987) (0)
1153-73 Moderate alcohol use is associated with reduced cardiovascular risk in patients following complicated acute myocardial infarction (2004) (0)
2177Cardiac resynchronization therapy in patients greater than 75 years of age - results from the European Society of Cardiology Survey II with 11 088 patients (2019) (0)
661 Innate immunity in heart failure following acute myocardial infarction (2005) (0)
Hemodynamic and Clinical Effects of Angiotensin II Receptor Antagonists in Heart Failure (1999) (0)
Angiotensin receptor blockers--finally the evidence is coming in: IDNT and RENAAL. (2002) (0)
Cardiac resynchronization therapy in the Czech Republic - Data from the EHRA CRT Survey II multicenter registry (2018) (0)
51 CRT SURVEY II: a european society of cardiology (ESC) survey of cardiac resynchronisation therapy in 11,088 patients an irish subset analysis (2019) (0)
Effect of Long-Terdn Enalapril Therapy on Cardiopulmonary Exercise Performance in Men With Mild Heart Failure and Previous Myocardial Infarction (2016) (0)
Reply to ‘Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease’ (2022) (0)
PREVALENCE, PREDICTORS AND EFFECTS OF NESIRITIDE ON CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE : RESULTS FROM ASCEND-HF (2013) (0)
M-001 A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED STUDY EVALUATING THE EFFECTS OF TWO DOSES OF LOSARTAN ON MORBIDITY AND MORTALITY IN CHINESE PATIENTS WITH SYMPTOMATIC HEART FAILURE INTOLERANT OF ACE INHIBITOR TREATMENT (HEAAL) (2011) (0)
Coronary flow reserve: a new target for treating hypertension (2009) (0)
Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials (2022) (0)
Abstract 17546: Effect of Intravenous Ferric Carboxymaltose on Symptoms and Quality of Life in Iron-Deficient Patients With Chronic Heart Failure With and Without Anemia: A Sub-Analysis of the FAIR-HF Trial (2010) (0)
Abstract 11150: Albuminuria in Heart Failure is More Strongly Associated with Markers of Congestion Than Renal Dysfunction (2021) (0)
INSULIN, LIXISENATIDE, AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME (2020) (0)
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction. (2023) (0)
What determines who gets Cardiac Resynchronization Therapy in Europe? A comparison between ESC-HF-LT registry, SwedeHF registry and ESC-CRT Survey II. (2023) (0)
University of Dundee Non-cardiac Comorbidities in Heart Failure with Reduced , Mid-range and Preserved Ejection (2018) (0)
Abstract 10904: The Seattle Post Myocardial Infarction Model (SPIM): Prediction of Mortality after Acute Myocardial Infarction (2012) (0)
Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction? (2005) (0)
Faculty Opinions recommendation of Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. (2007) (0)
The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France. (2019) (0)
[Digitalis therapy in patients with heart failure and sinus rhythm]. (1991) (0)
[Transdermal nitroglycerin. Evaluation against a placebo in a double-blind multi-cross-over study]. (1985) (0)
537CRT in women- results from the ESC CRT Survey II with 11 088 patients (2018) (0)
Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure (2020) (0)
[Digitalis in heart failure--still a therapeutic principle of current interest?]. (2001) (0)
2010 ESC Guideline Updates (2010) (0)
Potassium and the use of RAAS inhibitors in Heart Failure 5 with reduced ejection fraction : data from BIOSTAT-CHF 6 (2017) (0)
[Chronic left heart ventricle failure and inotropic stimulation]. (1995) (0)
Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction (2022) (0)
Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure (2023) (0)
5303Factors associated with guideline adherence - Results from ESC CRT survey II with 11 088 patients (2018) (0)
56-70: CRT Survey II (2016) (0)
128 Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF (2021) (0)
Atherosclerosis / Coronary Heart Disease Short-term Cholesterol Lowering Decreases Size and Severity of Perfusion Abnormalities by Positron Emission Tomography After Dipyridamole in Patients With Coronary Artery Disease : A Potential Noninvasive Marker of Healing Coronary Endothelium (2005) (0)
1087-106 Early serum levels of tissue inhibitor of metalloproteinases-1 but not matrix metalloproteinase-1 are associated with cardiovascular death after complicated myocardial infarction (2004) (0)
HbA1c is an independent predictor of total mortality in non-diabetic but not in diabetic patients with acute myocardial infarction and heart failure: a substudy to the OPTIMAAL trial (2003) (0)
Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial (2010) (0)
650 Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From ASCEND-HF (2012) (0)
DOES FEMALE SEX INFLUENCE HEART FAILURE AND SUDDEN DEATH AFTER MYOCARDIAL INFARCTION (2011) (0)
Three days hospital stay after uncomplicated primary PCI is feasible and does not influence the readmission rate (2013) (0)
[Chronic heart failure. A management program. Proposal for diagnosis and treatment]. (1994) (0)
[Treatment of heart failure with beta-blockaders]. (1997) (0)
Post-discharge prognosis of patients hospitalized for heart failure according to world-region and national levels of income and income-disparity in REPORT-HF: A cohort study (2019) (0)
537 Discontinuation of trial medication is related to increased mortality in a clinical trial (2003) (0)
P6392Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction (2018) (0)
Abstract 18347: Prognostic Significance of Activation Delay by Cross Correlation Analysis Using Tissue Doppler Imaging in Patients With Heart Failure and Narrow QRS Duration; an Echocardiography Guided Cardiac Resynchronization Therapy (Echo-CRT) Trial Substudy of Patients Not Randomized to CRT (2017) (0)
486 Subacute elevated N-BNP consistently predicts increased mortality and morbidity following complicated acute myocardial infarction, an OPTIMAAL substudy (2003) (0)
61 The relationship between N‐terminal B‐type natriuretic peptide and circulating markers of extracellular cardiac remodelling in patients following complicated myocardial infarction (2007) (0)
Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure (2021) (0)
535 Circulating markers of inflammation are independently related to markers of extracellular cardiac remodelling in patients following acute myocardial infarction (2008) (0)
P2630Incidence and prognostic impact of new-onset left bundle branch block in patients with heart failure and reduced ejection fraction (2019) (0)
Faculty Opinions recommendation of A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. (2006) (0)
Acuteandlong-term response toenalapril incongestive failure (1984) (0)
1488 Living with an Implantable Cardioverter Defibrillator. A Qualitative Study from one Norwegian Centre (2005) (0)
High Sensitivity Troponin I in Acute Decompensated Heart Failure (2011) (0)
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial (2001) (0)
PREVALENCE, PREDICTORS AND EFFECTS OF NESIRITIDE ON CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE (2013) (0)
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial (2022) (0)
[Physical exercise and heart failure. A review article]. (1996) (0)
Early discharge (third day) following primary PCI is associated with a high degree of patient satisfaction if patients are well informed prior to discharge (2013) (0)
CRT Survey II: a European Society of Cardiology (ESC) survey of cardiac resynchronization therapy—an Irish subset analysis (2020) (0)
Guideline recommendations for cardiac resynchronization therapy evolve but does clinical practice match the pace? (2018) (0)
What should be the focus in the management of patients with heart failure? The importance of peripheral vision. (2001) (0)
Impact of multimorbidity on mortality in HFrEF: Which comorbidities matter most? - An analysis of PARADIGM-HF and ATMOSPHERE. (2023) (0)
Living with an implantable cardioverter defibrillator: A qualitative study (2006) (0)
Abstract 17751: Predicting Cardiovascular Death in Patients With Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF/ATMOSPHERE Prognostic Model (2016) (0)
Abstract 19211: Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Improves Infarct Healing and Attenuates Left Ventricular Remodeling after Myocardial Infarction (2010) (0)
Impact of left ventricular ejection fraction phenotypes on healthcare-resource utilization in hospitalized heart failure: A secondary analysis of REPORT-HF. (2023) (0)
Guazzi et al Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Heart Failure (2009) (0)
Contents Vol. 134, 2016 (2016) (0)
Recurrent Infarction Causes the Most Deaths Following Myocardial Infarction With Left Ventricular Dysfunction (2005) (0)
556 N‐BNP during long term follow‐up in patients following complicated AMI, an OPTIMAL substudy (2003) (0)
Ischemic heart disease is more prevalent in low-income-countries and more often undertreated: data from report-hf (2020) (0)
Device Therapy in Heart Failure 2011 (2012) (0)
ESC Heart Failure Guidelines 2012 - a review (2013) (0)
patients with congestive heart failure Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in (2011) (0)
Acute Hemodynamic and Hormonal Effects of Mk-521 in Congestive Heart Failure. (1984) (0)
in Patients with Type 2 Diabetes and Acute Coronary Syndrome (2015) (0)
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure (2018) (0)
Abstract 9193: Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From ASCEND-HF (2012) (0)
309 Increased plasma levels of Matrix Metalloproteinase‐9 are related to a reduced systolic function in clinically stable long term survivors following high risk MI (2005) (0)
REVIEW PAPER Hints and tricks in the scientific publication (2005) (0)
Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure (2022) (0)
Abstracts of the Heart Failure Congress 2007 - Hamburg, Germany, 9-12 June, 2007 - Welcome address (2007) (0)
Abstract 3536: Circulating Markers of Collagen Turnover Following ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention Predict Infarct Size and Left Ventricular Volumes, Estimated by Serial Cardiac Magnetic Resonance Imaging for up to 1 Year (2009) (0)
Heart failure with normal LVEF in BIOSTAT-CHF. (2022) (0)
University of Dundee The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure Bayes-Genis, (2017) (0)
OP-EHEA180728 4269..4276 (2018) (0)
C33 - Efficacy of moexipril as add-on therapy to hydrochlorothiazide in patients with moderate to severe hypertension (1995) (0)
Response to Coceani: Cardiac resynchronization therapy has earned its class I recommendation and continues to thrive under scrutiny. (2010) (0)
89-04: Gender Effects of CRT in Patients with QRS Duration <130 ms in EchoCRT (2016) (0)
Second European Cardiac Resynchronisation Therapy Survey (Crt Survey Ii): Latvian Data Compared to Europe (2020) (0)
Benchmarking Belgian CRT practice against the rest of Europe: insights from the ESC-CRT survey II (2020) (0)
HYPOTENSION IN ACUTE DECOMPENSATED HEART FAILURE: FINDINGS FROM ASCEND-HF (2013) (0)
Hematinics in Patients with Complicated Acute Myocardial Infarction: Results from an OPTIMAAL Substudy (2008) (0)
Correction to: CRT Survey II: a European Society of Cardiology (ESC) survey of cardiac resynchronization therapy—an Irish subset analysis (2020) (0)
The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction (2013) (0)
Abstract 19027: Influence of Intravenous Ferric Carboxymaltose on Health-Related Quality of Life Measures in Patients with Chronic Heart Failure and Iron Deficiency: an Analysis from the FAIR-HF Study (2010) (0)
Coronary heart disease Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery disease (2006) (0)
Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. (2023) (0)
Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population. (2022) (0)
Cardiac resynchronisation therapy in heart failure patients with ischaemic vs non-ischaemic aetiology : results from 11088 patients in the ESC CRT Survey II (2018) (0)
ANGIOTENSIN II RECEPTOR ANTAGONISM AND HEART FAILURE : THE EVIDENCE (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kenneth Dickstein?

Kenneth Dickstein is affiliated with the following schools:

Kenneth Dickstein's Academic­Influence.com Rankings

Why Is Kenneth Dickstein Influential?

Kenneth Dickstein's Published Works

Published Works

What Schools Are Affiliated With Kenneth Dickstein?

Kenneth Dickstein's AcademicInfluence.com Rankings